Phaseline

Targets › CD8

CD8: drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: the race on CD8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Memorial Sloan Kettering Cancer CenterAntithymocyte globulin (ATG)
Polyclonal antibody targeting T lymphocytes; immunosuppressant
CTLA4, CD2, CD3, CD4, CD8Phase 1Myeloid Diseases; Hematologic MalignanciesMay 2027
AstraZenecaAZD6621
T cell-engaging antibody targeting STEAP2, CD3, and CD8
STEAP2, CD3, CD8Phase 1Prostate CancerMar 2029

Conditions

Myeloid Diseases (1) Hematologic Malignancies (1) Prostate Cancer (1)

Modalities

small molecule (2)

Companies

Memorial Sloan Kettering Cancer Center (1) AstraZeneca (1)

Related targets

CD3 (2) CTLA4 (1) CD2 (1) CD4 (1) STEAP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.